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Background: The optimal treatment for renal artery in-stent restenosis (RA- ISR) is not well established. Reintervention with balloon angioplasty, 
cutting-balloon, or additional bare-metal or drug-eluting stents can achieve immediate angiographic success. However, recurrent RA-ISR rates are high 
regardless of treatment strategy. Initial success with PTFE-covered stents, which may block in-growth of neointima, has led to expanded use for ISR.
Methods: We performed a retrospective analysis of PTFE-covered stents for the treatment of recurrent/refractory RA-ISR at 2 high volume vascular 
centers. Between December 2006 and August 2009, 30 renal arteries (26 patients) with RA-ISR were treated with balloon-expandable PTFE-covered 
stents. All patients had complete coverage of the prior stent(s). Procedural outcomes and restenosis rates by clinical follow-up, non-invasive imaging 
and/or angiography were evaluated.
Results: The study population consisted of 10 men and 16 women with a mean age of 70 +/- 11 years. Twelve (46%) of the patients had DM, 
100% had HTN, 100% had hypercholesterolemia, 16 (62%) were current or former smokers and all had peripheral arterial disease. The mean 
pre-procedure creatinine was 1.58 +/- 0.72 mg/dl. Five patients had a solitary functioning kidney. The average RA-ISR by angiography prior to 
intervention was 84 +/- 1.8 %. There was 100% procedural success without any recorded procedural complications. The median stent diameter 
was 6 mm; the median stent length was 16 mm. Post-dilation was performed in all patients with a median balloon diameter of 7 mm. All patients 
underwent either duplex ultrasonography or angiography. If restenosis was identified on duplex ultrasonography, repeat angiography was performed. 
On mean follow-up of 10.2 +/- 4.7 months, 0% of patients who received a PTFE-covered stent for RA-ISR had a severe enough renarrowing to require 
repeat intervention.
Conclusions: The use of PTFE-covered stent placement for RA-ISR appears safe and demontrates intermediate-term efficacy that may be superior 
compared to other percutaneous treatment modalities. Further studies on longer term patency are warranted.
